Overview
Company Does Not Provide H1B Sponsorship
Earli develops a cancer diagnostics platform that uses synthetic biology to create Synthetic Bioclassifiers. These genetic constructs enter cells and, if a cell is cancerous, activate and cause the cancer cell to produce a biomarker released into the bloodstream. The biomarker enables detection of cancer at very early stages by making cancer cells reveal themselves, addressing limitations of traditional liquid biopsies. The system is programmable to distinguish cancerous from healthy cells and is designed for partnerships with healthcare providers and pharmaceutical companies to commercialize the platform, with Accenture supporting its strategy.
Work here?Claim your company
Simplify's Take
What believers are saying
- Earli announced another $44M in 2026, bringing total funding to $104M.
- Accenture's 2024 strategic investment expands biopharma partnerships through Project Spotlight.
- Earli's Australia trial site list grew to Sydney, Melbourne, Frankston, and Adelaide.
What critics are saying
- Phase 1 was tiny; ten patients cannot validate sensitivity, specificity, or survival benefit.
- PET-reporter biology faces FDA scrutiny; one false-positive launch kills reimbursement by 2027.
- Without clear clinical superiority, large diagnostics partners abandon Earli and the platform stalls.
What makes Earli unique
- Earli programs cancer cells to emit PET-visible biomarkers, unlike standard liquid biopsies.
- Its 2026 platform combines AI-designed genetic switches with transient nanoplasmids and LNPs.
- Phase 1 Australia tested locally advanced lung cancer patients, proving human translational depth.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards